Abstract 887P
Background
Locally advanced laryngeal carcinoma is treated by concomitant chemotherapy and radiotherapy then surgery whenever possible. Most patients between 60-70 years refuse surgery, therefore, we designed a treatment in order to postpone or evade the surgical option in elderly patients with T3 and T4 disease.
Methods
In this prospective phase II trial, we included 120 patients diagnosed with locally advanced laryngeal carcinoma (84 patients with T3 disease versus 36 patients with T4 disease) aged between (60-74 years) 67 years in median. Study was started by weekly paclitaxel at a fixed dose of 150mg and carboplatin AUC4 taken on days 1,8 and 15 of a 21-day schedule, cycles were repeated for 6 times. Then patients were evaluated by CT scan and laryngoscopy. Complete responders, partial and non-responders are referred to concomitant radiotherapy (60 Gy) with weekly cisplatin at 50mg for 6 weeks. Patients were followed up for a median of 42 months (38-57 months). Study end point was objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) for 3 years. Secondary end point was toxicity profile.
Results
ORR was observed in 116 patients (96.6%) evaluated by clinical exam, CT scan and laryngoscopy. Complete clinical response was documented in 87 patients after completion of chemotherapy 72.5% (95% CI: 66.2-79.1) and 27.5% partial responders (95% CI: 23.4-31.7). At 3 years of follow-up, PFS was 95% (95% CI: 92.7-98.8) (p value 0.001) while the OS at 3 years was 95%. We have lost 4 patients who died after hospitalization for severe neutropenia and renal failure. Surgery was deleted as an option in this category of patients. The toxicity profile was composed of different grades of neutropenia/thrombocytopenia and anemia. Reversable acute renal failure was seen in 5 patients as well as alopecia. Peripheral neuropathy with different grades was documented in 92 patients.
Conclusions
Neoadjuvant chemotherapy followed by concomitant chemo-radiotherapy in the light of feasibility and acceptable toxicity profile can be a substitution for surgery in elderly patients with locally advanced laryngeal carcinoma taking into consideration the good tolerance and the modest toxicity profile.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received anyfunding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
782P - Predicting survival in malignant struma ovarii (MSO): A machine learning approach
Presenter: Sakhr Alshwayyat
Session: Poster session 02
Resources:
Abstract
783P - ESCAT gene actionability detection in early-stage ovarian: A descriptive analysis of an Italian referral center
Presenter: Floriana Camarda
Session: Poster session 02
784P - Prognostic nomograms for gestational and non-gestational choriocarcinoma: A population-based study
Presenter: Mustafa Alshwayyat
Session: Poster session 02
785P - Online prognostic calculator for gestational trophoblastic neoplasia (GTN): A tool for personalized treatment planning
Presenter: Zena Haddadin
Session: Poster session 02
786P - Exploring risk factors for recurrence in stage I uterine leiomyosarcomas: Is there a subgroup with a favorable prognosis?
Presenter: Alejandro Gallego
Session: Poster session 02
787P - First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors
Presenter: Ning Li
Session: Poster session 02
788P - Pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
Presenter: Natalie Ngoi
Session: Poster session 02
789P - Translational study and preliminary clinical trial of WX390 monotherapy in cancers with concurrence of PIK3CA and ARID1A mutations
Presenter: Jiajia Li
Session: Poster session 02
790P - The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynecologic tumors (GTs)
Presenter: Carmen Garcia Duran
Session: Poster session 02
791P - Activity of ERK1/2 inhibitor ASTX029 in patients with gynecological malignancies harboring genomic alterations in the MAPK pathway
Presenter: Geoffrey Shapiro
Session: Poster session 02